Entergy New Orleans LLC First Mor.../ US29364P5098 /
2024-05-09 10:10:00 PM | Chg. - | Volume | Bid10:00:01 PM | Ask2:00:00 AM | High | Low |
---|---|---|---|---|---|---|
21.49USD | - | 471 Turnover: 6,446.01 |
19.33Bid Size: 100 | 23.10Ask Size: 100 | 21.49 | 21.48 |
GlobeNewswire
6:00 AM
SPEE3D LAUNCHES EXPEDITIONARY MANUFACTURING UNIT (EMU) – THE COMPLETE MOBILE ADDITIVE MANUFACTURING ...
GlobeNewswire
5:01 AM
MKS Instruments Announces Pricing of Upsized Private Offering of $1.2 Billion of 1.25% Convertible S...
GlobeNewswire
4:10 AM
Kilmer Sports Ventures Enters into Exclusive Negotiations to Acquire French Professional Football Cl...
GlobeNewswire
3:50 AM
Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
3:00 AM
Infinera to Announce Preliminary Fiscal First Quarter 2024 Financial Results on May 14, 2024
GlobeNewswire
3:00 AM
GLOBAL LIFE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Bee...
GlobeNewswire
2:29 AM
AKRO INVESTOR ALERT: Edelson Lechtzin LLP Urges Akero Therapeutics, Inc. (NASDAQ: AKRO) Shareholders...
GlobeNewswire
2:06 AM
MBUU INVESTOR ALERT: Edelson Lechtzin LLP Urges Malibu Boats, Inc. (NASDAQ: MBUU) Shareholders With ...
GlobeNewswire
2:00 AM
ROSEN, A LEADING LAW FIRM, Encourages Rivian Automotive, Inc. Investors With Losses in Excess of $10...
GlobeNewswire
2:00 AM
HUTCHMED Initiates the RAPHAEL Registrational Phase III Trial of HMPL-306 for Patients with IDH1- an...
GlobeNewswire
2:00 AM
HUTCHMED Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatme...